Nobel Prize in Medicine-2025

Nobel Research Award-2024

American Academy of Dermatology, USA

Dr. Howard Maibach is a dermatologist with expertise in treating contact dermatitis (a rash caused by touching an irritating substance) and occupational dermatitis (a rash resulting from workplace exposure to an irritating substance). His specialties include allergic skin disorders and skin conditions caused by exposure to toxic substances. He also has an interest in dermatopharmacology, the study of medications for skin disorders. Maibach earned his medical degree from Tulane University School of Medicine. He completed a residency as well as a fellowship in dermatology at the Hospital of the University of Pennsylvania. Maibach has served on the editorial boards of more than 30 scientific journals. He is a member of 19 professional societies, including the American Academy of Dermatology, San Francisco Dermatological Society and International Commission on Occupational Health.

AstraZeneca, USA

University of Jeddah, Saudi Arabia

Dr. Mohammed Nabih Baeshen is a distinguished Professor of Microbial Biotechnology in the Department of Environmental Sciences at the College of Science, University of Jeddah. He earned his Ph.D. in Microbiology in 2009, M.Sc. in Parasitology in 2000, and B.Sc. in Zoology in 1992, all from King Abdulaziz University. Dr. Baeshen's academic journey includes serving as an Assistant Professor in various faculties at King Abdulaziz University from 2009 to 2013 and the University of Jeddah from 2013 to 2017. He later became an Associate Professor at the University of Jeddah in 2017 and was promoted to Professor in 2022. His administrative roles include Vice Dean of the College of Health Sciences (2012-2014), Vice Dean of the Faculty of Science (2017-2018), Chairman of the Biochemistry Department (2018-2020), and Chairman of the Physics Department (2019-2020) at the University of Jeddah. Dr. Baeshen's research interests focus on environmental sciences, environmental genomics (OMICS), and drug discovery from natural resources.

University of Algarve, Portugal

Pedro Fonte is an Assistant Professor at the Faculty of Sciences and Technology, University of Algarve, Portugal. He is an Integrated Member of the Center for Marine Sciences (CCMAR) at the University of Algarve and a Collaborative Researcher at the Institute for Bioengineering and Biosciences (iBB) at Instituto Superior Técnico, University of Lisbon. He has expertise on developing cutting-edge nanocarriers for drug delivery. His research is dedicated to pioneering targeted and controlled drug delivery systems that effectively cross biological barriers, enhancing treatment precision and efficacy. He is also a specialist in the lyophilization and solid-state characterization of pharmaceuticals and biopharmaceuticals, ensuring the stability and bioactivity of drugs. Moreover, his expertise extends to the structural characterization of therapeutic proteins, vital for advancing biopharmaceutical innovations. Currently, his groundbreaking work is primarily focused on revolutionary applications in cancer treatment and wound healing. Pedro Fonte has successfully coordinated several funded scientific projects, establishing valuable collaborations with researchers and academics worldwide. His publication record includes over 50 papers in high-impact peer-reviewed journals, 10 book chapters, and 1 edited book. His contributions to the scientific community and society have garnered him many awards and distinctions, including recognition as one of the Top 2% Scientists by Stanford University

Insitro,USA

Philip Tagari is insitro’s chief scientific officer, leading a team of multidisciplinary scientists and engineers who are redefining disease biology and implementing novel approaches to dramatically speed the delivery of meaningful therapeutics to patients with grievous disease. With more than 30 years of research and preclinical development experience, he brings expertise across neurobiology, metabolic disease, hematology/oncology, immunology and inflammation, cell and molecular biology, antibody discovery and biologics engineering, medicinal, peptide and oligonucleotide chemistry, analytical chemistry and biochemistry, structural biology, pharmacokinetics, safety pharmacology, laboratory automation and information technologies. Prior to insitro, Philip spent a decade as vice president of research (therapeutic discovery) at Amgen Inc. During that time, his global teams advanced over 30 innovative molecules into clinical development and commercialization including Lumukras® (first-in-class KRASG12C inhibitor); Tarlatamab (DLL3 BiTE®); AMG133 (anti-obesity bispecific) and Efavaleukin alfa (AMG 592) a novel IL-2 mutein Fc fusion. He is a director of CQDM (Consortium Quebecois sur la Decouverte du Medicament; Quebec Consortium for Drug Discovery) and SAB member for BenchSci (biology machine learning), NutcrackeRx (mRNA therapeutics) ad Amberstone Biosciences (novel biologics). Prior to joining Amgen in 1998, Philip was a research fellow at Merck Frosst (Canada) Inc, where he contributed to the discovery of Singulair® and Vioxx®, and performed basic research at McGill and Oxford Universities and the UK Medical Research Council.

University of Trieste,Italy